Press release
Leptomeningeal Metastases Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight
"Leptomeningeal Metastases Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Leptomeningeal Metastases Market.
The Leptomeningeal Metastases Pipeline report provides a thorough evaluation of both the commercial and clinical aspects of pipeline products, spanning from the pre-clinical development stage to the marketed phase. It includes a comprehensive description of each drug, encompassing its mechanism of action, clinical studies, any approvals through New Drug Applications (NDAs), and various product development activities. These activities involve technological advancements, collaborations, mergers and acquisitions, funding details, designations, and other pertinent information related to the product.
Some of the key takeaways from the Leptomeningeal Metastases Pipeline Report: https://www.delveinsight.com/sample-request/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Leptomeningeal Metastases treatment therapies with a considerable amount of success over the years.
• Leptomeningeal Metastases companies working in the treatment market are NanoLiposome Plus Therapeutics, AstraZeneca, TYK Medicine, Angiochem, and others, are developing therapies for the Leptomeningeal Metastases treatment
• Emerging Leptomeningeal Metastases therapies in the different phases of clinical trials are- Rhenium-186, AZD1390, TY-9591, ANG1005, and others are expected to have a significant impact on the Leptomeningeal Metastases market in the coming years.
• In July 2025, Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company specializing in targeted radiotherapeutics for central nervous system (CNS) cancers, announced that it will present the results of its ReSPECT-LM clinical trial orally and host a sponsored educational symposium at the upcoming SNO/ASCO CNS Metastases Conference.
• In May 2025, Single-dose rhenium (Re186) obisbemeda (Reyobiq; 186RNL) was found to be well tolerated and showed preliminary clinical benefits in patients with leptomeningeal metastases, as reported in the phase 1 dose-escalation ReSPECT-LM trial (NCT05034497).
• In April 2025, Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers using advanced platform technologies, has announced the online release of new data on its lead compound, REYOBIQTM (rhenium Re186 obisbemeda). This data will be featured in an abstract for both an oral presentation and a poster at the Nuclear Medicine and Neurooncology conference.
• In March 2025, The FDA has awarded orphan drug designation to the investigational radiotherapeutic rhenium (186Re) obisbemeda, recognizing its potential as a treatment for leptomeningeal metastases in lung cancer patients. Rhenium (186Re) obisbemeda is designed to deliver high-dose, highly targeted radiation directly to central nervous system (CNS) tumors, aiming to enhance both safety and efficacy by providing a more concentrated and localized radiation dose compared to existing therapies.
Leptomeningeal Metastases Overview
Leptomeningeal Metastases refers to the spread of cancer cells to the leptomeninges, the delicate membranes surrounding the brain and spinal cord. It occurs when malignant cells from primary tumors commonly breast cancer, lung cancer, or melanoma migrate through the bloodstream or cerebrospinal fluid (CSF) and infiltrate the central nervous system. LM can lead to neurological symptoms such as headaches, nausea, vomiting, vision changes, weakness, and cognitive impairment. It is considered a serious and often late-stage complication of cancer, requiring targeted therapies, intrathecal chemotherapy, or radiotherapy to manage symptoms and slow disease progression.
Get a Free Sample PDF Report to know more about Leptomeningeal Metastases Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Leptomeningeal Metastases Drugs Under Different Phases of Clinical Development Include:
• AZD1390: AstraZeneca
• TY-9591: TYK Medicine
• Rhenium-186: NanoLiposome Plus Therapeutics
• ANG1005: Angiochem
Leptomeningeal Metastases Pipeline Therapeutics Assessment
• Leptomeningeal Metastases Assessment by Product Type
• Leptomeningeal Metastases By Stage and Product Type
• Leptomeningeal Metastases Assessment by Route of Administration
• Leptomeningeal Metastases By Stage and Route of Administration
• Leptomeningeal Metastases Assessment by Molecule Type
• Leptomeningeal Metastases by Stage and Molecule Type
DelveInsight's Leptomeningeal Metastases Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Leptomeningeal Metastases product details are provided in the report. Download the Leptomeningeal Metastases pipeline report to learn more about the emerging Leptomeningeal Metastases therapies
https://www.delveinsight.com/sample-request/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Leptomeningeal Metastases Therapeutics Market include:
Key companies developing therapies for Leptomeningeal Metastases are - AstraZeneca, Angiochem., Plus Therapeutics, Y-mAbs Therapeutics, and others.
Leptomeningeal Metastases Pipeline Analysis:
The Leptomeningeal Metastases pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Leptomeningeal Metastases with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Leptomeningeal Metastases Treatment.
• Leptomeningeal Metastases key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Leptomeningeal Metastases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Leptomeningeal Metastases market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Leptomeningeal Metastases drugs and therapies
https://www.delveinsight.com/sample-request/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Leptomeningeal Metastases Pipeline Market Drivers
• Increasing Prevalence of Leptomeningeal Metastasess, increase in research and developmental activities are some of the important factors that are fueling the Leptomeningeal Metastases Market.
Leptomeningeal Metastases Pipeline Market Barriers
• However, high-cost associated with the disease, side-effects associated with the treatment and other factors are creating obstacles in the Leptomeningeal Metastases Market growth.
Scope of Leptomeningeal Metastases Pipeline Drug Insight
• Coverage: Global
• Key Leptomeningeal Metastases Companies: NanoLiposome Plus Therapeutics, AstraZeneca, TYK Medicine, Angiochem, and others
• Key Leptomeningeal Metastases Therapies: Rhenium-186, AZD1390, TY-9591, ANG1005, and others
• Leptomeningeal Metastases Therapeutic Assessment: Leptomeningeal Metastases current marketed and Leptomeningeal Metastases emerging therapies
• Leptomeningeal Metastases Market Dynamics: Leptomeningeal Metastases market drivers and Leptomeningeal Metastases market barriers
Request for Sample PDF Report for Leptomeningeal Metastases Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leptomeningeal Metastases Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight here
News-ID: 4258087 • Views: …
More Releases from DelveInsight Business Research
Global Surgical Simulation Market to reach USD 666.40 million by 2032 at a CAGR …
According to DelveInsight's analysis, The demand for surgical simulation solutions is largely fueled by the increasing prevalence of chronic diseases, including cancer. Moreover, the global rise in surgical procedures, along with expanding research and development (R&D) efforts and ongoing technological advancements in simulation devices, are significant factors driving the growth of the surgical simulation market during the forecast period from 2025 to 2032.
DelveInsight's "Surgical Simulation Market Insights, Competitive Landscape and…
Global Airway Clearance Devices for Cystic Fibrosis Market to grow at a CAGR of …
According to DelveInsight's analysis, The demand for airway clearance devices for cystic fibrosis is mainly fueled by the increasing prevalence of cystic fibrosis, rising cases of genetic disorders, expanded R&D efforts, and collaborative research among key industry players. These factors are expected to contribute significantly to the growth of the airway clearance devices market for cystic fibrosis during the forecast period from 2025 to 2032.
DelveInsight's "Airway Clearance Devices for Cystic…
Global Personal Care Contract Manufacturing Market to reach USD 42,720.21 millio …
According to DelveInsight's analysis, The increasing demand for personal care and cosmetic products is a major factor driving the growth of personal care contract manufacturing. This trend is largely supported by rising per capita income, which has led to higher consumer spending on beauty and personal care items. Additionally, government initiatives promoting the use of natural and organic products are further boosting market expansion. Collaborations and partnerships among key industry…
Global Digital Biomarkers Market to reach USD 14,478.78 million by 2032 at a CAG …
According to DelveInsight's analysis, The Digital Biomarkers Market is primarily driven by the rising prevalence of chronic diseases such as cardiovascular disorders, diabetes, and neurological conditions, which require continuous monitoring and early detection. Increasing adoption of wearable devices and mobile health technologies enables real-time, remote collection of physiological and behavioral data, enhancing patient care and treatment outcomes. Additionally, growing investments in digital health, advances in artificial intelligence and machine learning…
More Releases for Metastases
Why waiting for a diagnosis of "metastases is dangerous?
Why waiting is dangerous - New hope for metastases through immunotherapy with dendritic cells and "ImmuSeroForte"
The appearance of metastases in cancer is a shock for many patients and their relatives. In breast cancer in particular, but also in other types of tumor, metastases are often the turning point of the disease - they can become life-threatening.
But an important message is: waiting is not an option. The faster action is taken,…
Leptomeningeal Metastases Market Size, Share and Growth Report, 2034
Introduction
The Leptomeningeal Metastases (LM) market is gaining increased attention as survival rates for primary cancers improve, leading to higher detection of late-stage complications like LM. This rare but severe condition occurs when cancer cells spread to the leptomeninges and cerebrospinal fluid (CSF), most often from breast cancer, lung cancer, or melanoma. Historically associated with poor prognosis, LM treatment is evolving with advancements in molecular diagnostics, targeted therapies, intrathecal drug delivery…
Rising Liver Disease Cases Drive Growth In Liver Metastases Treatment Market Dri …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Liver Metastases Treatment Market Size By 2025?
The market for treating liver metastases has seen significant growth in the past few years. It is projected to increase from $1.57 billion in 2024 to $1.71 billion in 2025, with a compound annual growth rate (CAGR) of…
Treatment of metastases
As an affected patient, you are aware of one thing: when you are diagnosed with cancer, everything changes, from your quality of life to your everyday life. Surgical removal of the primary tumor is often attempted. If this does not work, radiotherapy or chemotherapy is tried, and hormone therapy is also used for certain types of cancer. Most doctors who do not work scientifically are skeptical of the new forms…
Shaping the Liver Metastases Treatment Market in 2025: Advancements In Liver Met …
How Big Is the Liver Metastases Treatment Market Expected to Be, and What Will Its Growth Rate Be?_x000D_
The market for liver metastases treatments has seen significant growth in the past years. The market size is predicted to increase from $1.57 billion in 2024 to $1.71 billion in 2025, with a compound annual growth rate (CAGR) of 8.9%. Factors contributing to the growth during the historic period include the development of…
Leptomeningeal Metastases Treatment Market Size, Forecast, Drugs, and Companies …
Leptomeningeal Metastases Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Leptomeningeal Metastases Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Leptomeningeal Metastases, historical and…
